45 patents currently held
2 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
56 more records may belong here and await a decision; they are not counted.
The next term ends in Jan 2028. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
14
Ending by 2030
Jan 2028
Next term end
36
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Oct 2031 · High confidence
Also notable
Ends May 2036 · High confidence
Also notable
Ends Nov 2028 · High confidence
Two-Stage Ultrafiltration/Diafiltration
US 8,772,461
The most cited patent in this portfolio, cited by 27 later US patents, top 25% of utility patents granted in 2014 in our data. Protection runs to 2031.
Method for the Treatment or Prevention of Infection-Related Immune Conditions Using a Composition Comprising Igm
US 9,913,903
The largest patent family in this portfolio, 5 related applications, renewed at every maintenance window due so far. Protection runs to 2036.
Recombinantly Modified Plasmin
US 8,101,394
Renewed at every maintenance window since the 2012 grant; no more fees are due before its term ends in 2028.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 25, 2027The maintenance fee for Compositions, Methods And/Or Kits Comprising a Recombinant Human CD38-Extracellular Domain (US 11,708,418) comes due Jan 25, 2027. Unpaid by Jul 26, 2027, it lapses early.
- 1 fee due Mar 1, 2027The maintenance fee for Immunochromatography Devices, Methods and Kits (US 9,121,857) comes due Mar 1, 2027. Unpaid by Sep 1, 2027, it lapses early.
- 1 fee due Aug 25, 2027The maintenance fee for Method for Treating Infectious Diseases Using a Composition Comprising Plasma-Derived Immunoglobulin M (IgM) (US 10,570,194) comes due Aug 25, 2027. Unpaid by Feb 25, 2028, it lapses early.
- 2 fees due Sep 1 to 5, 2027 · next Sep 1
Recent changes
- 5 of the patents on this record were granted since Aug 18, 2026
- 1 term has ended since Aug 18, 2026
What they patent
The 5 largest of its 36 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Method for the Treatment or Prevention of Infection-Related Immune Conditions Using a Composition Comprising Igm | 3 in force | to May 2036 |
| Recombinantly Modified Plasmin | 3 in force | to Nov 2028 |
| System and Method for the Sterile Filling of Containers | 2 in force | to May 2041 |
| Method for Treating Infectious Diseases Using a Composition Comprising Plasma-Derived Immunoglobulin M (IgM) | 2 in force | to May 2036 |
| HCV NS4A/MODIFIED NS3 Polypeptides and Uses Thereof | 2 in force | to Jun 2035 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,290,820 | Method for Detection of Parvovirus B19 held by Grifols Therapeutics LLC In force · High confidence | In force | High confidence | |
| US 8,231,869 | Recombinant Plasmin for Opthalmic Indications held by Grifols Therapeutics LLC In force · High confidence | In force | High confidence | |
| US 8,101,394 | Recombinantly Modified Plasmin held by Grifols Therapeutics LLC In force · High confidence | In force | High confidence | |
| US 8,182,808 | Recombinantly Modified Plasmin held by Grifols Therapeutics LLC In force · High confidence | In force | High confidence | |
| US 8,512,980 | Recombinantly Modified Plasmin held by Grifols Therapeutics LLC In force · High confidence | In force | High confidence | |
| US 8,841,082 | Method and Device for the Determination of Minor Cell Population in Heterogeneous Cell Populations In force · High confidence | In force | High confidence | |
| US 8,560,246 | Method for Adjusting Results of a Polymerase Chain Reaction (PCR) Instrument held by Grifols Therapeutics LLC In force · High confidence | In force | High confidence | |
| US 9,725,501 | Two-Stage Ultrafiltration/Diafiltration held by Grifols Therapeutics LLC In force · High confidence | In force | High confidence | |
| US 8,852,585 | Method of Treatment and Prophylaxis of Diseases Related to Amyloid Deposition Using Igm held by Grifols Therapeutics LLC In force · High confidence | In force | High confidence | |
| US 8,617,863 | Composition, Method, and Kit for Preparing Plasmin held by Grifols Therapeutics LLC In force · High confidence | In force | High confidence |
Also on record, not counted in the 45: 2 patents in force now held by others · 42 patents ended · 37 applications pending · 25 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.